Sino Biopharmaceutical Limited (USD) Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Sino Biopharmaceutical Limited (USD) Active

Office Tower, Wan Chai, HK

Stock Price USD

Price Change

Last Dividend USD

SBHMY's stock peer is ACRV (Acrivon Therapeutics, Inc. Common Stock)

SBHMY's stock peer is ACXP (Acurx Pharmaceuticals, Inc.)

SBHMY's stock peer is ALRN (Aileron Therapeutics, Inc.)

SBHMY's stock peer is ANEB (Anebulo Pharmaceuticals, Inc.)

SBHMY's stock peer is CNTA (Centessa Pharmaceuticals plc)

SBHMY's stock peer is CYT (Cyteir Therapeutics, Inc.)

SBHMY's stock peer is DTCFF (Defence Therapeutics Inc.)

SBHMY's stock peer is ELDN (Eledon Pharmaceuticals, Inc.)

SBHMY's stock peer is ENLV (Enlivex Therapeutics Ltd.)

SBHMY's stock peer is FENC (Fennec Pharmaceuticals Inc.)

SBHMY's stock peer is GNFT (Genfit S.A.)

SBHMY's stock peer is KZR (Kezar Life Sciences, Inc.)

SBHMY's stock peer is LBPH (Longboard Pharmaceuticals, Inc.)

SBHMY's stock peer is MRES (Institute of Biomedical Research Corp.)

SBHMY's stock peer is NUVL (Nuvalent, Inc.)

SBHMY's stock peer is OPT (Opthea Limited)

SBHMY's stock peer is PTIX (Protagenic Therapeutics, Inc.)

SBHMY's stock peer is RNXT (RenovoRx, Inc.)

SBHMY's stock peer is TARS (Tarsus Pharmaceuticals, Inc.)

SBHMY's stock peer is TPST (Tempest Therapeutics, Inc.)

SBHMY's stock peer is TRDA (Entrada Therapeutics, Inc.)

SBHMY's stock peer is XOMA (XOMA Corporation)

SBHMY's stock peer is ZIVO (ZIVO Bioscience, Inc.)

Healthcare Biotechnology

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2024-09-11	2024-10-18	0.08	1.93 %	Quarterly
2024-06-12	2024-07-22	0.08	1.78 %	Quarterly
2023-10-05	2023-11-13	0.05	2.84 %	Quarterly
2023-06-21	2023-07-31	0.15	3.18 %	Quarterly
2022-09-07	2022-10-13	0.15	2.54 %	Quarterly
2022-06-16	2022-07-27	0.10	1.48 %	Quarterly
2021-09-13	2021-10-19	0.05	1.20 %	Quarterly
2021-06-18	2021-07-27	0.10	0.94 %	Quarterly
2020-12-14	2021-01-15	0.05	0.94 %	Quarterly
2020-09-14	2020-10-15	0.05	0.77 %	Quarterly
2020-06-12	2020-07-21	0.15	0.59 %	Quarterly
2019-12-10	2020-01-13	0.08	0.76 %	Quarterly
2019-09-12	2019-10-15	0.08	0.73 %	Quarterly
2019-06-14	2019-07-19	0.15	1.04 %	Quarterly
2018-12-05	2019-01-07	0.08	0.84 %	Quarterly
2018-09-11	2018-10-15	0.08	0.65 %	Quarterly
2018-06-04	2018-07-10	0.15	0.31 %	Quarterly
2017-11-28	2018-01-02	0.08	0.18 %	Quarterly
2017-09-18	2017-10-16	0.08	0.24 %	Quarterly

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions